Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
217.87
Dollar change
+0.85
Percentage change
0.39
%
IndexS&P 500 P/E29.14 EPS (ttm)7.48 Insider Own0.29% Shs Outstand88.20M Perf Week1.77%
Market Cap18.50B Forward P/E14.93 EPS next Y14.59 Insider Trans-2.61% Shs Float84.65M Perf Month3.98%
Income661.20M PEG- EPS next Q3.26 Inst Own98.59% Short Float / Ratio3.64% / 3.75 Perf Quarter6.15%
Sales13.54B P/S1.37 EPS this Y-20.66% Inst Trans-2.81% Short Interest3.08M Perf Half Y15.01%
Book/sh92.73 P/B2.35 EPS next Y7.36% ROA3.42% Target Price241.54 Perf Year7.28%
Cash/sh8.57 P/C25.41 EPS next 5Y-3.18% ROE6.98% 52W Range179.58 - 222.76 Perf YTD7.70%
Dividend1.82 P/FCF18.55 EPS past 5Y3.41% ROI5.07% 52W High-2.20% Beta1.05
Dividend %0.83% Quick Ratio1.20 Sales past 5Y8.10% Gross Margin25.11% 52W Low21.32% ATR3.42
Employees80000 Current Ratio1.36 Sales Q/Q-15.23% Oper. Margin9.45% RSI (14)63.35 Volatility1.94% 1.38%
OptionableYes Debt/Eq0.80 EPS Q/Q-45.84% Profit Margin4.88% Rel Volume0.63 Prev Close217.02
ShortableYes LT Debt/Eq0.66 EarningsOct 26 BMO Payout15.47% Avg Volume821.66K Price217.87
Recom1.69 SMA203.05% SMA505.95% SMA2007.68% Volume521,481 Change0.39%
Date Action Analyst Rating Change Price Target Change
Sep-06-23Initiated HSBC Securities Hold $210
Dec-12-22Downgrade Citigroup Buy → Neutral $275 → $250
Sep-19-22Downgrade Argus Buy → Hold
Aug-22-22Resumed Morgan Stanley Overweight $300
Jan-28-22Downgrade Deutsche Bank Buy → Hold $330 → $294
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Nov-30-23 07:46PM
Nov-27-23 08:35AM
Nov-24-23 07:21AM
Nov-22-23 05:04AM
Nov-20-23 07:00AM
07:00AM Loading…
Nov-16-23 07:00AM
Nov-08-23 07:00AM
Nov-06-23 05:07AM
Oct-31-23 01:17AM
Oct-28-23 02:29PM
Oct-27-23 08:30AM
08:30AM
Oct-26-23 11:13PM
04:19PM
02:51PM
10:36AM Loading…
10:36AM
09:30AM
08:48AM
08:15AM
08:08AM
07:06AM
06:58AM
Oct-23-23 06:26AM
Oct-19-23 10:01AM
Oct-16-23 08:30PM
Oct-13-23 08:28AM
Oct-12-23 06:56AM
Oct-11-23 08:30AM
07:30AM
Oct-05-23 10:08AM
04:25PM Loading…
Oct-04-23 04:25PM
Sep-29-23 06:57AM
Sep-28-23 09:06AM
Sep-27-23 11:15AM
Sep-19-23 07:20AM
05:00AM
Sep-14-23 06:56AM
Sep-11-23 07:45PM
Sep-04-23 12:06PM
Aug-28-23 10:40AM
Aug-17-23 09:26PM
Aug-15-23 05:38AM
Aug-14-23 03:15PM
Aug-08-23 04:05PM
Aug-07-23 09:57AM
09:57AM
Aug-03-23 02:56PM
08:35AM
07:00AM
Jul-31-23 06:57AM
Jul-28-23 02:15PM
02:48AM
Jul-27-23 03:24PM
02:31PM
02:24PM
01:00PM
11:38AM
08:44AM
08:41AM
07:09AM
06:57AM
02:00AM
Jul-26-23 11:04AM
Jul-24-23 04:27PM
07:22AM
Jul-20-23 10:02AM
Jul-19-23 12:14PM
Jul-17-23 09:13AM
Jul-13-23 08:00AM
06:58AM
Jul-11-23 03:01PM
07:00AM
Jul-07-23 12:00PM
Jul-03-23 07:05AM
06:57AM
Jun-29-23 09:58PM
07:02AM
Jun-28-23 06:08PM
Jun-14-23 08:59AM
Jun-12-23 06:30PM
05:28PM
11:18AM
Jun-09-23 05:18PM
04:51PM
04:43PM
Jun-08-23 09:08AM
Jun-07-23 01:18PM
07:00AM
Jun-05-23 06:57AM
Jun-02-23 12:56PM
12:41PM
Jun-01-23 08:39AM
May-31-23 04:35PM
May-26-23 06:52AM
06:32AM
May-25-23 11:30AM
May-17-23 02:15PM
May-16-23 02:32PM
10:59AM
07:00AM
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilkinson Peter JSVP, Chief Accounting OfficerNov 16Sale210.711,384291,6272,087Nov 20 12:23 PM
ANDERSON KERRII BDirectorAug 08Sale211.575,0001,057,83215,275Aug 10 08:55 AM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 29Sale240.0021250,8807,605Jul 03 11:52 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19Option Exercise182.514,300784,79317,246May 23 08:06 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19Sale216.914,300932,70712,946May 23 08:06 AM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18Option Exercise130.601,500195,9008,187May 22 03:08 PM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18Sale216.771,500325,1556,687May 22 03:08 PM
Schroeder Mark SEVP, President-Diagnostics LabMar 31Sale225.813,897879,9826,687Apr 03 10:05 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentFeb 21Option Exercise182.513,000547,53017,069Feb 23 09:54 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentFeb 21Sale250.588,0002,004,6759,069Feb 23 09:54 AM
Schroeder Mark SEVP, President-Diagnostics LabFeb 14Sale247.6330976,5186,687Feb 16 12:51 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 07Sale243.0140999,3916,687Feb 09 09:04 AM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 07Sale243.0121953,2195,341Feb 09 09:27 AM
Schroeder Mark SEVP, President-Diagnostics LabFeb 03Sale253.9032482,2646,687Feb 06 03:51 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 03Sale253.9017343,9255,341Feb 06 03:56 PM